Last updated: August 26, 2026
Lyrica, Pfizer’s pregabalin franchise, generated approximately $5 billion in global revenue in 2018 before U.S. generic entry. The product then entered a rapid erosion cycle after U.S. pediatric exclusivity ended on June 30, 2019. Lyrica remains commercially relevant through generic pregabalin, international markets, controlled-substance demand, and differentiated formulations, but Pfizer’s branded revenue exposure has declined sharply.
What is Lyrica and how large was the market?
Lyrica is the brand name for pregabalin, an alpha-2-delta ligand that reduces calcium-channel-mediated neurotransmitter release. The FDA approved Lyrica in December 2004 for diabetic peripheral neuropathy and postherpetic neuralgia. Subsequent U.S. approvals covered fibromyalgia and adjunctive therapy for partial-onset seizures.[1]
| Attribute |
Lyrica profile |
| Active ingredient |
Pregabalin |
| Originator |
Pfizer |
| Initial U.S. approval |
December 30, 2004 |
| Drug class |
Alpha-2-delta calcium-channel ligand |
| U.S. controlled status |
Schedule V |
| Principal dosage forms |
Capsules, oral solution, extended-release tablets |
| Major branded indications |
Neuropathic pain, fibromyalgia, partial-onset seizures |
| Peak global revenue period |
2017-2018 |
| U.S. generic entry |
2019 |
| Current market structure |
Primarily generic pregabalin, with residual branded and international demand |
Lyrica’s commercial growth came from expansion beyond epilepsy into neuropathic pain and fibromyalgia. Pain indications supported a much larger addressable market than seizure treatment alone. Pfizer also benefited from high chronic-use rates, prescription refills, and broad physician familiarity.
How did Lyrica revenue change before and after generic entry?
Pfizer’s Lyrica revenue rose to approximately $5 billion globally in 2018, then fell after U.S. generic competition began.
| Fiscal year |
Approximate Pfizer Lyrica revenue |
Market event |
| 2016 |
$3.2 billion |
Continued growth before major U.S. loss of exclusivity |
| 2017 |
$4.5 billion |
Strong global sales and broader pain use |
| 2018 |
$5.0 billion |
Peak commercial period |
| 2019 |
$3.3 billion |
U.S. generic entry began midyear |
| 2020 onward |
Materially lower and no longer a major Pfizer growth driver |
Generic substitution and portfolio deprioritization |
Sources report slightly different figures depending on currency treatment, product reporting conventions, and whether regional revenue is grouped with Pfizer’s broader Established Pharmaceuticals business. Pfizer’s 2018 Form 10-K reported Lyrica revenue of about $4.97 billion, while the 2019 Form 10-K reported approximately $3.32 billion.[2,3]
The 2019 decline was not caused by demand collapse. It reflected the loss of U.S. branded pricing power. Generic pregabalin entered with substantial price discounts, and pharmacy benefit managers rapidly substituted generic capsules and oral solution.
When did Lyrica lose U.S. exclusivity?
Lyrica’s practical U.S. loss of exclusivity occurred on June 30, 2019, when six-month pediatric exclusivity associated with the product expired. The underlying composition patent had expired earlier, but the pediatric extension delayed full generic marketing for six months.[4]
Key U.S. exclusivity dates
| Milestone |
Date |
| FDA approval of Lyrica |
December 30, 2004 |
| New chemical entity exclusivity |
Expired in 2009 |
| Core composition patent nominal expiry |
December 30, 2018 |
| Pediatric exclusivity expiry |
June 30, 2019 |
| Broad U.S. generic launch window |
July 2019 |
The timing created a defined “cliff” rather than a gradual erosion period. Once the pediatric extension ended, multiple approved ANDA holders could compete in the U.S. market.
What patents protected Lyrica?
Lyrica’s principal U.S. protection came from pregabalin composition patents and later method-of-use, formulation, and dosage-form patents.
Core composition patent
| Patent |
Subject matter |
Relevance |
| U.S. Patent No. 6,197,819 |
GABA analog compounds, including pregabalin-related chemistry |
Principal composition protection commonly associated with Lyrica |
The ’819 patent was granted in 2001 and had a patent term extending into late 2018, subject to the six-month pediatric extension. The patent covered the active pharmaceutical ingredient rather than only a specific brand presentation.[5]
Method-of-use patents
Pfizer pursued method-of-use protection for conditions including:
- Neuropathic pain
- Fibromyalgia
- Partial-onset seizures
- Other pain-related treatment methods
Method-of-use patents can delay approval or launch of generics only for the protected indication. They do not necessarily prevent approval for non-infringing indications. Generic applicants can use “skinny labels” that omit patented uses under the FDA’s regulatory framework.[6]
The legal value of these patents was limited compared with composition protection because generic pregabalin could enter for unpatented uses while omitting selected protected indications. The commercial effect depended on prescribing behavior, pharmacy substitution rules, labeling language, and whether the patented indication drove most prescriptions.
Formulation and extended-release patents
Pfizer also developed Lyrica CR, an extended-release pregabalin product intended for once-daily administration. The formulation used controlled-release delivery to alter exposure and dosing convenience.
Lyrica CR did not replace the commercial scale of immediate-release Lyrica. Its market impact was limited by:
- The established use of twice-daily immediate-release capsules
- Generic substitution pressure
- Lower physician switching incentives
- Limited differentiation in a mature neuropathic-pain market
- The availability of low-cost immediate-release pregabalin
Formulation patents can protect release profiles, excipient systems, tablet architecture, and dosing regimens. They do not restore the broad protection lost when the active ingredient becomes generic.
What was the Orange Book status of Lyrica?
Lyrica was listed in the FDA Orange Book with patents and regulatory exclusivities relevant to generic approval and launch timing. The most commercially important listing was the composition patent covering pregabalin. Later listings covered specific methods of use and extended-release presentations.[4]
Orange Book listings mattered in three ways:
- They required ANDA applicants to make patent certifications.
- Paragraph IV certifications created potential patent litigation.
- Listed patents could trigger a 30-month stay of approval under the Hatch-Waxman Act if the brand holder sued within the statutory period.
The regulatory effect differed by dosage form. Immediate-release capsules faced the most significant generic pressure because they represented the principal Lyrica market. Extended-release products had a separate patent and approval analysis.
Which companies challenged Lyrica through Paragraph IV filings?
Several generic manufacturers pursued U.S. approval for pregabalin capsules and oral solution. The competitive group included companies such as Teva, Mylan, Amneal, Alembic, Dr. Reddy’s Laboratories, and other ANDA applicants.
Paragraph IV challenges asserted that listed patents were invalid, unenforceable, or not infringed. Pfizer responded through Hatch-Waxman litigation and commercial settlements. The settlements allowed generic entry in 2019 rather than permitting an immediate uncapped launch before the end of pediatric exclusivity.
The practical outcome was controlled delay followed by multi-source competition. This structure protected a portion of Pfizer’s pre-expiry revenue but did not prevent severe post-entry price erosion.
What patent litigation affected Lyrica?
Lyrica’s most important litigation involved the scope and enforceability of second medical-use patents for pain indications.
Warner-Lambert v. Actavis in the United Kingdom
The U.K. litigation between Warner-Lambert, a Pfizer company, and Actavis examined whether a generic manufacturer could market pregabalin for non-patented indications while omitting the patented pain indication from its label. The U.K. Supreme Court issued its decision in 2018 and rejected key aspects of Warner-Lambert’s infringement theory.[7]
The case had commercial importance beyond the parties because it addressed:
- Skinny-label practices
- Prescribing and dispensing behavior
- Indirect infringement
- Second medical-use patent enforcement
- The evidentiary burden for proving that a generic product is being used for a patented indication
The decision reduced the leverage of method-of-use patents over a multisource molecule. It also reinforced the difficulty of using indication patents to block generic entry when the active ingredient has several therapeutic uses.
What generic entry risks existed for Lyrica?
Lyrica faced high generic-entry risk because it had the characteristics that normally produce rapid erosion:
- A small-molecule active ingredient
- High prescription volume
- Multiple approved generic applicants
- Mature manufacturing technology
- No biologic comparability barrier
- Broad use across chronic conditions
- Limited clinical differentiation from generic pregabalin
- Strong payer incentives to substitute
Generic launch scenarios
| Scenario |
Commercial effect |
| One authorized generic or limited competition |
Moderate price erosion and slower share loss |
| Several simultaneous generic launches |
Rapid loss of branded volume and price |
| Skinny-label launches |
Entry for non-patented uses, with litigation around induced infringement |
| Formulation-specific competition |
Slower erosion for extended-release products, but limited total-market protection |
| International staggered entry |
Regional revenue decline at different speeds |
The actual U.S. market followed the multi-source scenario. Pfizer’s branded revenue declined quickly after July 2019, while generic pregabalin became the dominant volume product.
Does Lyrica face biosimilar risk?
No. Lyrica is a synthetic small-molecule drug, not a biologic. It does not face biosimilar competition under the FDA’s Biologics Price Competition and Innovation Act pathway.
The relevant threat is generic competition under the Abbreviated New Drug Application pathway. Generic pregabalin must demonstrate pharmaceutical equivalence and bioequivalence, not biosimilarity. This creates a lower regulatory barrier than the development of a biosimilar to a complex biologic.
What is the international patent and exclusivity picture?
Lyrica’s international exclusivity ended at different times by jurisdiction and indication. Pfizer faced particularly important litigation in the United Kingdom over the enforceability of pain-related second medical-use claims. European generic entry also developed on a country-by-country basis, reflecting national patent litigation, supplementary protection certificates, reimbursement systems, and local launch strategies.
International market dynamics differed from the U.S. because:
- Patent terms and SPC periods varied by country
- Second medical-use patents received different treatment
- Tender systems accelerated price reductions in some markets
- Reimbursement rules affected branded retention
- Local generic manufacturers had different launch capabilities
In Europe, the product’s brand value was also affected by the regulatory debate over “skinny labeling” and whether pharmacies could substitute pregabalin for patented indications.
How strong is the Lyrica patent estate?
Lyrica’s patent estate was strong before composition protection expired but materially weaker afterward.
| Patent category |
Historical strength |
Post-expiry value |
| Composition patent |
Very high |
Expired; no longer blocks generic active ingredient |
| Method-of-use patents |
Moderate |
Indication-specific and difficult to enforce broadly |
| Extended-release formulation patents |
Moderate |
Protects a narrower product segment |
| Manufacturing patents |
Variable |
Can create supplier barriers but rarely blocks all generic production |
| Pediatric exclusivity |
High timing value |
Expired June 30, 2019 |
| Regulatory exclusivity |
Limited after 2009 |
No longer material |
The estate’s strongest asset was the composition patent. Once it expired, remaining patents could support targeted litigation and product segmentation but could not preserve the original branded monopoly.
What manufacturing and intellectual-property barriers remain?
Pregabalin manufacturing is technically manageable for established generic manufacturers. The active ingredient requires control of stereochemistry, impurity profiles, crystallinity, and process reproducibility. These requirements create quality and scale barriers but do not represent a durable monopoly.
Potential manufacturing-related protections include:
- Chiral synthesis and resolution processes
- Polymorph control
- Crystallization conditions
- Intermediate compounds
- Impurity limits
- Extended-release matrix systems
- Tablet coating and dissolution profiles
A generic manufacturer can often design around process patents by using a different synthesis route. Manufacturing patents therefore have lower blocking power than composition patents unless the protected process is unusually efficient or the active ingredient is difficult to source.
How does Lyrica compare with competing neuropathic-pain drugs?
Lyrica competed with gabapentin, duloxetine, amitriptyline, topical lidocaine, opioids, and other pain therapies. Its main commercial competitors differed by indication.
| Drug |
Primary positioning |
Patent and generic status |
Competitive effect |
| Pregabalin/Lyrica |
Neuropathic pain, fibromyalgia, seizures |
Generic after 2019 |
Price-led substitution |
| Gabapentin/Neurontin |
Neuropathic pain, seizures |
Long generic history |
Low-cost alternative |
| Duloxetine/Cymbalta |
Neuropathic pain, depression |
Generic after 2013 |
Competes in diabetic neuropathy and mood-linked pain |
| Amitriptyline |
Neuropathic pain |
Generic |
Low-cost, older therapy |
| Tapentadol/Nucynta |
Pain |
Controlled substance, branded and generic competition |
Alternative for selected patients |
| Opioids |
Acute and chronic pain |
Mostly generic |
Safety and regulatory constraints limit use |
Pregabalin retained advantages in predictable dosing, physician familiarity, and efficacy across several approved uses. Its commercial disadvantage after 2019 was the loss of branded price protection.
What licensing deals and corporate transactions shaped Lyrica?
Lyrica originated within Warner-Lambert’s pharmaceutical research portfolio. Pfizer acquired Warner-Lambert in 2000, obtaining rights to pregabalin before U.S. approval. The transaction placed Lyrica within Pfizer’s global commercial infrastructure and provided access to Pfizer’s regulatory, manufacturing, and distribution capabilities.
There was no major post-launch licensing transaction that altered Lyrica’s central commercial economics. The principal strategic event was Pfizer’s acquisition of Warner-Lambert, followed by internal lifecycle management around indications, dosage forms, and international commercialization.
What is the FDA regulatory status of pregabalin?
Pregabalin remains FDA-approved and commercially available in multiple dosage forms. The FDA-approved product category includes:
- Immediate-release capsules
- Oral solution
- Extended-release tablets for selected indications
Generic pregabalin is approved through ANDAs. The product’s Schedule V status reflects recognized abuse and dependence risks, although its control level is lower than that of opioid analgesics. The regulatory classification affects prescribing, dispensing, monitoring, and market access.
The post-expiry market is therefore regulated but mature. FDA approval does not provide meaningful differentiation between branded and generic immediate-release products when the labels, strength options, and bioequivalence profiles are comparable.
What was Pfizer’s revenue exposure to Lyrica?
At its peak, Lyrica represented one of Pfizer’s largest individual products and a material share of its innovative or established medicines revenue. Approximately $5 billion in annual sales created substantial exposure to:
- U.S. patent expiry
- Generic substitution
- Litigation outcomes
- Pricing pressure
- International patent timing
- Product-cycle management
The 2019 sales decline demonstrated the sensitivity of Pfizer’s earnings to a high-revenue small-molecule loss of exclusivity. The company’s broader portfolio reduced the absolute financial impact, but Lyrica’s fall illustrated the difference between revenue concentration and long-term franchise durability.
What is the current commercial outlook for Lyrica?
The branded Lyrica franchise is a mature post-exclusivity asset. Future value is concentrated in generic pregabalin volume, selected branded prescriptions, international markets, and differentiated extended-release use.
The primary market drivers are:
- Generic price competition and pharmacy substitution.
- Chronic neuropathic-pain prevalence.
- Prescriber concerns about sedation, dizziness, edema, and misuse.
- Payer preference for low-cost alternatives.
- Competition from gabapentin and duloxetine.
- Potential changes in controlled-substance enforcement.
- Demand in emerging markets where branded recognition remains relevant.
The commercial ceiling is lower than during the patent-protected period. Growth is more likely to come from total pregabalin utilization than from branded pricing or market exclusivity.
Key Takeaways
- Lyrica is pregabalin, a small-molecule drug originally developed by Warner-Lambert and commercialized by Pfizer.
- Global revenue peaked at approximately $5 billion in 2018.
- U.S. pediatric exclusivity ended June 30, 2019, enabling broad generic entry.
- The core composition patent provided the principal barrier to competition and expired in late 2018, subject to the pediatric extension.
- Method-of-use and formulation patents offered narrower protection than the composition patent.
- Warner-Lambert v. Actavis limited the practical reach of second medical-use patent enforcement in the United Kingdom.
- Lyrica faces generic, not biosimilar, competition.
- Pfizer’s revenue declined from about $5 billion in 2018 to approximately $3.3 billion in 2019 as U.S. generics launched.
- The current market is driven by low-cost generic pregabalin, chronic pain demand, payer substitution, and international pricing.
- The remaining patent estate has limited ability to recreate the original Lyrica monopoly.
FAQs About Lyrica Patents, Generics, and Market Economics
Can a generic manufacturer sell pregabalin for all Lyrica indications?
A generic manufacturer may market approved indications that are not covered by enforceable patents. It may use a label that omits a patented indication, although prescribing, dispensing, and inducement issues can still create litigation risk.
Did Lyrica receive pediatric exclusivity?
Yes. Pediatric exclusivity extended the relevant U.S. protection period by six months, delaying broad generic marketing until June 30, 2019.
Is Lyrica CR protected separately from Lyrica capsules?
Yes. Extended-release tablets involve separate formulation, dosage-form, labeling, and patent analyses. Their protection does not restore exclusivity for immediate-release pregabalin capsules.
Why did Lyrica sales fall faster than many mature branded drugs?
Multiple generic applicants entered near the same time after pediatric exclusivity ended. Pregabalin had high prescription volume, straightforward substitution economics, and limited clinical differentiation from the generic product.
Is pregabalin still commercially attractive for generic manufacturers?
Yes. Margins are lower than during the branded period, but chronic use, broad prescribing, multiple strengths, and established demand support a large multisource market. Profitability depends on manufacturing cost, channel access, supply reliability, and competition intensity.
References
- U.S. Food and Drug Administration. (2004). Lyrica prescribing information. FDA.
- Pfizer Inc. (2018). 2018 annual report. Pfizer.
- Pfizer Inc. (2019). 2019 annual report. Pfizer.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
- U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,197,819, GABA analogs. USPTO.
- U.S. Food and Drug Administration. (2018). Approved drug products with therapeutic equivalence evaluations: Patent and exclusivity information. FDA.
- Supreme Court of the United Kingdom. (2018). Warner-Lambert Company LLC v. Actavis Laboratories FL, Inc. and others [2018] UKSC 56. UK Supreme Court.
